Mendus Management

Management criteria checks 2/4

Mendus' CEO is Erik Manting, appointed in Mar 2021, has a tenure of 4.17 years. directly owns 9.32% of the company’s shares, worth €2.56M. The average tenure of the management team and the board of directors is 4.2 years and 3.8 years respectively.

Key information

Erik Manting

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	4.2yrs
CEO ownership	9.3%
Management average tenure	4.2yrs
Board average tenure	3.8yrs

Recent management updates

Recent updates

CEO

Erik Manting (53 yo)

4.2yrs

Tenure

Dr. Erik Manting, Ph D., has been the Chief Executive Officer at Mendus AB (publ) (formerly known as Immunicum AB (publ)) since March 16, 2021 and served as its Chief Business Officer and Deputy Chief Exec...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Erik Manting	Chief Executive Officer	4.2yrs	no data	9.32% € 2.6m
Alex Karlsson-Parra	Co-Founder & Chief Scientific Officer	17.3yrs	SEK 1.42m	0.078% € 21.4k
Lotta Ferm	Chief Financial Officer	4.3yrs	no data	0.27% € 73.8k
Leopold Bertea	Chief Technology Officer	3yrs	no data	0.12% € 32.9k
Tariq Mughal	Chief Medical Officer	no data	no data	no data

4.2yrs

Average Tenure

59yo

Average Age

Experienced Management: 1YG0's management team is considered experienced (4.2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Ada Kruisbeek	Chair of Scientific Advisory Board	3.7yrs	no data	no data
Sven Andreasson	Independent Chairman	5.1yrs	SEK 705.00k	0.050% € 13.7k
Lewis L. Lanier	Member of Scientific Advisory Board	1.9yrs	no data	no data
Hans Preusting	Independent Director	4yrs	SEK 380.00k	0.020% € 5.5k
Helen Tuvesson	Independent Director	5.1yrs	SEK 355.00k	0.0063% € 1.7k
Tanja de Gruijl	Member of Scientific Advisory Board	3.7yrs	no data	no data
Dharminder Chahal	Independent Director	4.3yrs	SEK 370.00k	0.53% € 144.6k
Inge Svane	Member of Scientific Advisory Board	6.7yrs	no data	no data
Sjoerd van Burg	Member of Scientific Advisory Board	3.7yrs	no data	no data
Ted Fjallman	Independent Director	1.4yrs	SEK 310.00k	no data

3.8yrs

Average Tenure

62yo

Average Age

Experienced Board: 1YG0's board of directors are considered experienced (3.8 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/07 14:06
End of Day Share Price	2025/05/07 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Mendus AB (publ) is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jyoti Prakash	Edison Investment Research
Soo Romanoff	Edison Investment Research
Stefan Wård	Pareto Securities

Mendus Management

Management criteria checks 2/4

Key information

Recent management updates

Mendus AB (Publ) Announces Chief Medical Officer Changes

Mendus AB (publ), Annual General Meeting, May 09, 2025

Mendus AB (Publ) Announces Board Changes

Mendus AB (Publ) Announces Board Changes

Mendus AB (Publ) Appoints Ted Fjällman as Board Member

Mendus AB (publ), Annual General Meeting, May 17, 2024

Recent updates

Mendus AB (Publ) Announces Chief Medical Officer Changes

Mendus AB (publ) to Report Q1, 2025 Results on May 06, 2025

Mendus AB Presents Positive Survival Data from the Ongoing Advance II Phase 2 Trial at the ASH 2024 Conference

New major risk - Revenue size

Mendus AB (publ), Annual General Meeting, May 09, 2025

Mendus AB (publ) to Report Fiscal Year 2024 Final Results on Apr 18, 2025

New major risk - Revenue and earnings growth

No longer forecast to breakeven

Now 24% overvalued

Forecast to breakeven in 2025

Mendus AB (Publ) Announces Board Changes

Mendus AB (Publ) Announces Board Changes

Mendus AB (publ) Announces Ethics Committee Approval for the AMLM22-CADENCE Trial with Lead Product Vididencel in AML

New major risk - Financial position

Mendus AB (Publ) Announces Clinical Pipeline Update

Mendus AB (Publ) Appoints Ted Fjällman as Board Member

Mendus AB Announces Positive Survival Data from Phase 2 Advance II Trial Evaluating Vididencel as Maintenance Therapy for AML at ASH 2023

Mendus AB (publ) to Report Q3, 2024 Results on Nov 08, 2024

Mendus AB (publ), Annual General Meeting, May 17, 2024

Mendus Announces Phase 1 vididencel Clinical Trial Results in AML and High-Risk MDS Patients Published in Peer-Reviewed Medical Journal

Mendus AB (Publ) Announces Multiple Abstracts to Be Presented At Ash 2023 Including Oral Presentation on Advance Ii Survival Data

Mendus AB to Present Novel Data Supporting the Broad Potential of its Proprietary Cancer Vaccine Platform at CICON23

Mendus AB Receives U.S. FDA Fast Track Designation forididencel in Acute Myeloid Leukemia

New minor risk - Profitability

Forecast breakeven date pushed back to 2025

New major risk - Shareholder dilution

Mendus AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 90 million.

New major risk - Market cap size

Mendus AB Appoints Lewis Lanier to Scientific Advisory Board

Mendus AB Presents Comprehensive Advance II Immunomonitoring Data at the EHA Annual Meeting 2023

Mendus AB (publ) announced that it expects to receive funding from Flerie Invest AB

No longer forecast to breakeven

Forecast breakeven date pushed back to 2024

Mendus AB (publ) to Report Fiscal Year 2022 Final Results on Apr 17, 2023

Mendus AB (publ) to Report Q1, 2023 Results on May 12, 2023

Mendus AB (publ) Presents Positive Survival Data from the Advance II Trial Evaluating DCP-001 as A Maintenance Therapy in AML At the American Society of Hematology Meeting

Forecast to breakeven in 2023

High number of new and inexperienced directors

Mendus AB Announces Nomination Committee for 2023 Annual General Meeting

Mendus to Report Positive Clinical and Preclinical Data in Ovarian Cancer At the European Society of Gynaecological Oncology 2022 Congress

Mendus AB (Publ) Publishes Preclinical Data Demonstrating Significant Anti-Tumor Synergies of Intratumoral Immune Priming with CTLA-4 Inhibition

Immunicum AB (publ) Announces Positive Interim Results from ADVANCE II Study in AML Maintenance Treatment

Immunicum AB Presents Preclinical Data Demonstrating Synergy of Dcp-001 with Standard Treatments for Acute Myeloid Leukemia

High number of new and inexperienced directors

Immunicum AB (publ) to Report Fiscal Year 2021 Final Results on Apr 15, 2022

Immunicum AB (publ) to Report Q1, 2022 Results on May 10, 2022

Immunicum Presents Phase II Data Demonstrating Reduced MRD and Improved Survival with DCP-001 Treatment in AML Patients at ASH 2021

Forecast to breakeven in 2023

Immunicum Announces Completion of Phase Ib Portion and Early Closure of ILIAD Study

Immunicum AB Publishes DCP-001 Mechanism of Action in the Journal Cells

Immunicum Announces Enrollment of First Patient in Phase I ALISON Study Evaluating Cancer Relapse Vaccine Candidate DCP-001 in Ovarian Cancer

Chief Executive Officer recently bought €241k worth of stock

Independent Director has left the company

Immunicum AB Presents Preclinical Data for Ilixadencel and DCP-001 At the 18Th Cancer Immunotherapy Annual Meeting

Immunicum AB (Publ) Announces Updated Executive Management Team After Business Combination

Chief Medical Officer has left the company

Immunicum AB Appoints Jeroen Rovers, M.D., Ph.D., to the Position of Chief Medical Officer

Immunicum Announces Survival Benefit in Phase II MERECA Trial of Ilixadencel in Kidney Cancer

New 90-day low: €0.67

Immunicum AB Receives Orphan Drug Designation from EMA for Ilixadencel as Treatment for Gastrointestinal Stromal Tumors

Independent Chairman Michael S. Oredsson has left the company

Immunicum AB (Publ) Announces Executive Changes

Immunicum AB (publ) Approves Election of New Board Members

Immunicum AB (publ) Announces Transitions in Board of Directors

New 90-day low: €0.70

Immunicum AB (publ) Receives FDA Orphan Drug Designation for Ilixadencel as a Treatment for Hepatocellular Carcinoma (HCC)

Immunicum AB (publ) Announces Changes to the Nomination Committee

Immunicum AB (publ) (OM:IMMU) completed the acquisition of DCPrime B.V. from Van Herk Investments B.V. and others.

Immunicum AB (Publ) Announces Completion of Patient Recruitment for Phase Ib Portion of ILIAD Combination Clinical Trial